Elenara da Fonseca Andrade Procianoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elenara da Fonseca Andrade Procianoy has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Edna Lúcia Souza
Universidade Federal da Bahia
1 shared publication Fernando Antônio de Abreu e Silva
Pediatric Pulmonology Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
1 shared publication- Gabriel Souza Medrado Nunes
Federal University of Bahia, Salvador, Brazil
1 shared publication - Laís Ribeiro Mota
Universidade Federal da Bahia, Brazil
1 shared publication - Luciana de Freitas Velloso Monte
Hospital da Criança de Brasília José Alencar Universidade Católica de Brasília Brasília Federal District Brazil
1 shared publication - Luiz Vicente Ribeiro Ferreira da Silva Filho
Universidade de São Paulo
1 shared publication
Latest Publications
- 10 March 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (3) , e71557
CFTR Modulators in Brazil: Not for Everyone—A Comparison of Ineligibility Across Different Regions
Objectives: To evaluate the prevalence of ineligibility for Elexacaftor/Tezacaftor/Ivacaftor (ETI) and Ivacaftor (IVA) and to compare data from four centers in Brazil, considering the racial/ethnic background of each population. Methods: This cross‐sectional study used data from the Brazilian Cystic Fibrosis (CF) Registry. Individuals with a confirmed diagnosis of CF by the identification of two variants in the CFTR gene and/or elevated sweat chloride levels were included. Variables studied were treatment center, age at diagnosis, current age, sex, race/ethnicity, genotype, and ineligibility for ETI and IVA. The chi‐square test compared the distribution of race/ethnicity across centers and associations between ineligibility, treatment center, and the presence of the 3120 + 1 G > A variant. Binary logistic regression was applied to assess the strength of association between the main variables. Results: Six hundred forty‐nine individuals were included, with a median age at diagnosis and current age of 0.25 and 11.6 years, respectively. One hundred thirty‐eight participants (21.26%) were ineligible for ETI or IVA. Racial/ethnic distribution varied across centers, in the total sample, and among ineligible individuals. Non‐White individuals were 20% more likely to be ineligible than White individuals. The ineligibility for ETI did not vary significantly among the centers. Conclusions: The ineligibility for ETI was high across all analyzed regions, but was not different among the centers. In Brazil, characterized by widespread admixture, the public health policies must consider the genotypic heterogeneity and wide variation in ancestry of the Brazilian population.
- 10 March 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (3) , e71557
CFTR Modulators in Brazil: Not for Everyone—A Comparison of Ineligibility Across Different Regions
Objectives: To evaluate the prevalence of ineligibility for Elexacaftor/Tezacaftor/Ivacaftor (ETI) and Ivacaftor (IVA) and to compare data from four centers in Brazil, considering the racial/ethnic background of each population. Methods: This cross‐sectional study used data from the Brazilian Cystic Fibrosis (CF) Registry. Individuals with a confirmed diagnosis of CF by the identification of two variants in the CFTR gene and/or elevated sweat chloride levels were included. Variables studied were treatment center, age at diagnosis, current age, sex, race/ethnicity, genotype, and ineligibility for ETI and IVA. The chi‐square test compared the distribution of race/ethnicity across centers and associations between ineligibility, treatment center, and the presence of the 3120 + 1 G > A variant. Binary logistic regression was applied to assess the strength of association between the main variables. Results: Six hundred forty‐nine individuals were included, with a median age at diagnosis and current age of 0.25 and 11.6 years, respectively. One hundred thirty‐eight participants (21.26%) were ineligible for ETI or IVA. Racial/ethnic distribution varied across centers, in the total sample, and among ineligible individuals. Non‐White individuals were 20% more likely to be ineligible than White individuals. The ineligibility for ETI did not vary significantly among the centers. Conclusions: The ineligibility for ETI was high across all analyzed regions, but was not different among the centers. In Brazil, characterized by widespread admixture, the public health policies must consider the genotypic heterogeneity and wide variation in ancestry of the Brazilian population.
- 16 November 2019
- Published by Springer Nature in Lung
- Vol. 198 (1) , 151-156
Chloride Conductance, Nasal Potential Difference and Cystic Fibrosis Pathophysiology
Cystic fibrosis (CF) is a multisystem genetic disease caused by dysfunction of the epithelial anionic channel Cystic Fibrosis Transmembrane conductance Regulator (CFTR). Decreased mucociliary clearance because of thickened mucus is part of the pulmonary disease pathophysiology. It is controversial if the thickened airway surface liquid (ASL) is caused by the deficient chloride secretion and excessive sodium (through ENaC) and water hyperabsorption from the periciliar fluid or by the lack of bicarbonate secretion with relative acidification of the ASL. Correlations between the magnitude of in vivo chloride conductance with phenotypic characteristics and CF genotype can help to elucidate these mechanisms and direct to new treatments.
- 16 November 2019
- Published by Springer Nature in Lung
- Vol. 198 (1) , 151-156
Chloride Conductance, Nasal Potential Difference and Cystic Fibrosis Pathophysiology
Cystic fibrosis (CF) is a multisystem genetic disease caused by dysfunction of the epithelial anionic channel Cystic Fibrosis Transmembrane conductance Regulator (CFTR). Decreased mucociliary clearance because of thickened mucus is part of the pulmonary disease pathophysiology. It is controversial if the thickened airway surface liquid (ASL) is caused by the deficient chloride secretion and excessive sodium (through ENaC) and water hyperabsorption from the periciliar fluid or by the lack of bicarbonate secretion with relative acidification of the ASL. Correlations between the magnitude of in vivo chloride conductance with phenotypic characteristics and CF genotype can help to elucidate these mechanisms and direct to new treatments.